Stand UP to Rheumatoid Arthritis (SUPRA)
ConditionRheumatoid Arthritis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMarie Hudson, MD
About this trial
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Eligibility criteria
Qualifiers
Age ≥ 18 years;
Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).
Disqualifiers
Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;
Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;
Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;
Unable to provide consent or complete forms (alone or with assistance) in English or French
Trial design
Treatments tested in this trial
- TNFi
- Anti-IL6
- JAKi
Treatment groups
75 Participants
are divided into 4 treatment groupsSponsors and collaborators
Marie Hudson, MD
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Sponsor institution
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator
Montreal General Hospital
Collaborator
Lady Davis Institute
Collaborator
Source ClinicalTrials.gov